QualityDipStocks / Health Care · Medical Specialities
CareDx CDNA
Outside our quality screen, so we don’t track its dips. It’s 2% below its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −2%
- Risk vs market
- Above marketbeta 1.18
3 bullish · 5 bearish See why
Repriced or dip?
Near its high
The price is 2% below its 52-week high (Oct 30), but the business held up: shares outstanding fewer shares, each owns more, earnings per share +4.9%, operating margin 0.0 pts.
Some numbers held up (shares outstanding fewer shares, each owns more, earnings per share +4.9%, operating margin 0.0 pts), others slipped. The price is 2% below its 52-week high.
The price is 2% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
52-wk high: P/E 37.4×; 52-wk low: P/E 11.1×; now: P/E 35.0×.
| High | Low | Now | |
|---|---|---|---|
| Price | $87.41Oct 30 | $14.52Nov 4 | $85.88 |
| Implied growth | n/a | n/a | n/a |
| P/E | 37.4× | 11.1× | 35.0× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for CDNA: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much CDNA moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 5.9× the S&P 500’s.
- Beta vs S&P 500
- 1.18
- Volatility
- 76% vs 13% SPY
- Correlation SPY
- 0.20
- Correlation QQQ
- 0.16
How it ranks
Where CDNA stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 2 of 3 measures
- Dividends + buybacks yield0.5% · cash paid out or used to retire shares, vs market capLowest 26%of 1,836
- Revenue growth, last 12 months+39% · vs the 12 months beforeTop 11%of 1,814
- Operating margin23% · of sales kept as operating profitTop 21%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
ProfitabilityOperating margin widened to −8.1% in FY2025 from −72.5% in FY2023 (SEC filings).
GrowthSales grew 39% to $497M over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityReturn on equity of 33% over the last 12 months, up 66 points in two years.
Top bearish points 5 of 5
ValuationPrice / book of 9.6×, above the 5.2× median for the 217 Health Care companies we cover.
GrowthSales grew 5.7% a year over the last three fiscal years, below the 11% median for the 199 Health Care companies we cover.
ValuationP/E of 35.0×, above the 29.0× median for the 135 Health Care companies we cover.
Cash returnsShare count up 2.3% over 12 months, above the +0.8% median for the 203 Health Care companies we cover.
QualityDoesn’t pass our quality screen: no positive free cash flow.
All fundamentals
P/E 35.0 · ROE 33% · Sales +39%
Valuation
- P/E
- 35.0×Health Care median 29.0×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 9.05×
- Price / book
- 9.63×
- Market cap
- $4.5Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $497M
- Sales growth, 12 months
- +38.9%vs the 12 months before
- Sales growth, 3 yrs
- +5.7%/yrfrom FY2022
- Diluted EPS, 12 months
- $2.37
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $129M
- Net income growth
- +83%12 months vs before
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 23.4%
- Net margin
- 25.9%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 33%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $250M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $24M0.5% of market cap
- Share count, 1 year
- +2.3%diluted shares vs a year ago
- Stock-based comp
- $38M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From CareDx’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
Sales +39%
- Gross margin71%
- Operating margin8%
- Return on invested capital14%
- Return on equity33%
- Sales growth (latest quarter vs year-ago quarter)+39%
- Net debt / EBITDA−8.6×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $85.88
- 52-wk lowlowest close, 1 year$14.52−83.1%
- PriceMon Nov 2 close$85.88you are here
- 52-wk highhighest close, 1 year$87.41+1.8%
Momentum & 52-week range
RSI 78 · 5 days +24.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
CDNA is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on CareDx in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical Specialities
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.